Page 93 - Read Online

Page 292 Schwarzenbach et al. Cancer Drug Resist 2019;2:271-96 I http://dx.doi.org/10.20517/cdr.2019.010

35. Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, et al. Genomic and epigenomic signatures in ovarian cancer associated with
resensitization to platinum drugs. Cancer Res 2018;78:631-44.
36. Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, et al. The cyclin-dependent kinase inhibitor p57(Kip2) is
epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
Br J Cancer 2012;106:482-9.
37. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and
clinical outcomes in ovarian cancer. Cancer Res 2011;71:3317-27.
38. Iramaneerat K, Rattanatunyong P, Khemapech N, Triratanachat S, Mutirangura A. HERV-K hypomethylation in ovarian clear cell
carcinoma is associated with a poor prognosis and platinum resistance. Int J Gynecol Cancer 2011;21:51-7.
39. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance
of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010;127:555-67.
40. Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, et al. Epigenetic inactivation of the putative DNA/RNA helicase
SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 2016;7:3084-97.
41. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to
platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer 2009;125:1454-63.
42. Olkhov-Mitsel E, Bapat B. Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers. Cancer Med
2012;1:237-60.
43. Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. Biology (Basel) 2016;5:E3.
44. Guilleret I, Losi L, Chelbi ST, Fonda S, Bougel S, et al. DNA methylation profiling of esophageal adenocarcinoma using methylation
ligation-dependent macroarray (MLM). Biochem Biophys Res Commun 2016;479:231-7.
45. Kagohara LT, Stein-O'Brien GL, Kelley D, Flam E, Wick HC, et al. Epigenetic regulation of gene expression in cancer: techniques,
resources and analysis. Brief Funct Genomics 2018;17:49-63.
46. Cock-Rada A, Weitzman JB. The methylation landscape of tumour metastasis. Biol Cell 2013;105:73-90.
47. Deng J, Wang L, Chen H, Hao J, Ni J, et al. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian
cancer. Oncotarget 2016;7:55771-88.
48. Surana R, Sikka S, Cai W, Shin EM, Warrier SR, et al. Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta
2014;1845:53-65.
49. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Curr Cancer Drug Targets 2008;8:187-98.
50. Fazio C, Ricciardiello L. Inflammation and Notch signaling: a crosstalk with opposite effects on tumorigenesis. Cell Death Dis
2016;7:e2515.
51. Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a
balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 2019;26:25.
52. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23.
53. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-78.
54. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
55. Holzer AK, Katano K, Klomp LW, Howell SB. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human
ovarian carcinoma cells. Clin Cancer Res 2004;10:6744-9.
56. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer
drugs. Mol Pharmacol 2010;77:887-94.
57. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, et al. High resistance to cisplatin in human ovarian cancer cell lines is
associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
58. Jendzelovsky R, Jendzelovska Z, Hilovska L, Koval J, Mikes J, et al. Proadifen sensitizes resistant ovarian adenocarcinoma cells to
cisplatin. Toxicol Lett 2016;243:56-66.
59. Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers (Basel) 2019;11:E119.
60. Nie J, Liu L, Li X, Han W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid
tumors. Cancer Lett 2014;354:12-20.
61. Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist 2013;18:619-24.
62. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, et al. Integrated analysis of DNA methylation and gene expression reveals specific
signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009;2:34.
63. Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets
2013;13:379-99.
64. Samudio-Ruiz SL, Hudson LG. Increased DNA methyltransferase activity and DNA methylation following epidermal growth factor
stimulation in ovarian cancer cells. Epigenetics 2012;7:216-24.
65. Granados ML, Hudson LG, Samudio-Ruiz SL. Contributions of the epidermal growth factor receptor to acquisition of platinum
resistance in ovarian cancer cells. PLoS One 2015;10:e0136893.
66. Zhao Y, Li Q, Wu X, Chen P. Upregulation of p27Kip1 by demethylation sensitizes cisplatin-resistant human ovarian cancer SKOV3
cells. Mol Med Rep 2016;14:1659-66.
67. Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, et al. Tribbles 2 mediates cisplatin sensitivity and DNA damage
response in epithelial ovarian cancer. Int J Cancer 2017;141:1600-14.